Voyageur Pharmaceuticals Expands into Mexican Healthcare Market Through Distribution Partnership

Voyageur Pharmaceuticals Ltd. has entered into a non-exclusive distribution agreement with Mexican pharmaceutical distributor PHALANX, Comercializadora e Importadora de Componentes SA DE CV, marking a significant expansion of the Canadian company's presence in Latin American healthcare markets. The agreement follows a non-binding Letter of Intent announced in June 2025 and establishes a strategic partnership focused on market expansion into Mexico's medical imaging sector.

Under the distribution framework, Phalanx will register Voyageur's barium contrast media products with Mexican health regulatory authorities and distribute them through its established network. Voyageur will provide support throughout the regulatory approval and commercialization process, working collaboratively to advance market access. This partnership aligns with Voyageur's international growth strategy and represents a key milestone in expanding the company's global footprint.

Brent Willis, CEO of Voyageur, stated that this agreement reflects the company's commitment to expanding global access to innovative, cost-effective imaging solutions. Latin America represents a critical market in Voyageur's expansion plan, with this partnership establishing groundwork for long-term growth. Sales of Voyageur's barium sulfate contrast media products in Mexico and other Latin American countries will be subject to local regulatory approval processes, with Phalanx taking the lead in preparing and submitting necessary filings.

Phalanx brings extensive expertise to the partnership, with over 20 years of experience in iodine and gadolinium contrast media for radiology and deep knowledge of the Mexican public health landscape. The company specializes in market entry strategies, distribution, and business development in Spanish-speaking Latin America, providing comprehensive commercial intelligence and strategic market solutions for businesses entering the region. More information about Voyageur's operations and products can be found at https://voyageurpharmaceuticals.ca.

Voyageur's expansion into Mexico comes as the company pursues its vision of becoming the first vertically integrated company in the radiology contrast media drug market. The company owns the Frances Creek Project, which contains rare mineral resources suitable for pharmaceutical applications. Voyageur believes its natural barium products will replace current synthetic products in the pharmaceutical marketplace with higher quality imaging solutions. The partnership with Phalanx represents an important step in Voyageur's broader strategy to establish itself as a key player in global contrast media markets while addressing the need for cost-effective medical imaging solutions in underserved regions.